Muyuan Foods (SZ:002714) 2 1 Shi Ji Jing Ji Bao Dao·2025-11-29 14:22Core Viewpoint - The company Muyuan Foods Co., Ltd. has re-submitted its application for an IPO on the Hong Kong Stock Exchange after its initial submission expired, aiming for dual listing in both A-shares and H-shares markets [1][3]. Group 1: Company Overview - Muyuan Foods is the largest pig farming enterprise in China, having been listed on the A-share market since 2014 [1]. - As of November 28, 2025, the A-share price was CNY 50.75, reflecting a 1.7% increase [1][2]. - The company has maintained its position as the world's largest pig producer since 2021, with a global market share of 5.6% as of 2024 [4][6]. Group 2: Financial Performance - Revenue figures for Muyuan Foods from 2022 to 2024 were CNY 1248.26 billion, CNY 1108.61 billion, and CNY 1379.47 billion, respectively [5]. - In the first half of 2025, the company reported revenue of CNY 764.63 billion and a net profit of CNY 107.9 billion, with a gross margin increase from 7.7% in the first half of 2024 to 19.0% in the first half of 2025 [5]. Group 3: Strategic Initiatives - The IPO funds are intended for expanding overseas markets, enhancing R&D across the entire industry chain, and focusing on breeding, smart farming, nutritional management, and biosecurity [6]. - The company aims to leverage growth opportunities in emerging markets where per capita meat consumption is still low, such as Vietnam, the Philippines, and Thailand [6]. Group 4: Shareholding and Leadership - The direct controlling shareholder is Muyuan Industrial Group Co., Ltd., holding 15.54% of shares, while the chairman and president, Qin Yinglin, holds 20.86 billion shares [5]. - Qin Yinglin and his wife are ranked as the richest individuals in Henan province with a wealth of CNY 187 billion [6]. Group 5: Debt and Financial Risks - The company has shown significant changes in its debt structure, with net current liabilities reaching CNY 155.89 billion, CNY 310.76 billion, CNY 241.58 billion, and CNY 166.37 billion from 2022 to mid-2025 [8]. - The company acknowledges potential liquidity risks due to its past net current liabilities and the impact of external factors on its biological assets [8].